Agreement to Accelerate Development and Commercialization of Closed-Loop Artificial Pancreas System
Friday, July 22, 2016
Tandem Diabetes Care®, a medical device company and manufacturer of a family of innovative touchscreen insulin pumps, and TypeZero Technologies, a digital health and personalized medicine company, announced that they have entered into a License Agreement allowing Tandem to integrate TypeZero’s artificial pancreas (“AP”) technology into a next-generation t:slim® Insulin Pump.
TypeZero’s AP tech has been used in over 28 clinical studies with over 475 participants. The tech has treat-to-target algorithms that were developed by TypeZero based on initial research done by the University of Virginia.
“This agreement with TypeZero is a significant step in our shared vision to bring a best-in-class, closed-loop artificial pancreas system to the diabetes community as quickly as possible,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care.
“Partnering with Tandem to deliver an artificial pancreas device that leverages Tandem’s deep expertise in user-centered design and human factors research is very exciting for the future of diabetes management,” said Chad Rogers, founder and CEO of TypeZero Technologies. “We believe that bringing our artificial pancreas technology together with Tandem’s innovative insulin pump platform will revolutionize the way patients manage their diabetes.”
While financial details of the License Agreement have not been disclosed, the announcement did explain that it includes a worldwide, non-exclusive license for the use of TypeZero’s AP tech in future Tandem products. Tandem will also have access to TypeZero’s future AP tech over the next five years. The two companies plan to work together closely to expedite the clinical research associated with the development of Tandem’s closed-loop AP system.